45
Participants
Start Date
March 31, 2006
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
Capecitabine (Xeloda)
1000mg/m\^2 administered orally twice daily for two weeks followed by one week rest period
Bevacizumab
7.5 mg/kg IV will be administered every 3 weeks
Comprehensive Cancer Centers of Nevada, Las Vegas
UCLA Medical Center, Los Angeles
Cancer Care Associates Medical Group, Inc., Redondo Beach
Pacific Shores Medical Group, Long Beach
North Valley Hematology/Oncology Medical Group, Northridge
Wilshire Oncology Medical Group, Inc., Pomona
Central Hematology Oncology Medical Group, Inc., Alhambra
Virginia K. Crosson Cancer Center, Fullerton
Ventura County Hematology-Oncology Specialists, Oxnard
Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara
Comprehensive Blood and Cancer Center, Bakersfield
Central Coast Medical Oncology Corporation, Santa Maria
Collaborators (1)
Genentech, Inc.
INDUSTRY
Translational Oncology Research International
OTHER